|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Igm Biosciences, Inc. (IGMS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,220,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Co.'s primary product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. Co.'s second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 proteins. Co.'s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell targeting CD38 and CD3 proteins and IGM-2537, a bispecific T cell targeting CD123, and CD3 proteins.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
395,317 |
928,010 |
1,130,933 |
1,203,433 |
| Total Buy Value |
$3,425,569 |
$6,857,033 |
$8,606,797 |
$9,889,100 |
| Total People Bought |
1 |
1 |
5 |
6 |
| Total Buy Transactions |
3 |
6 |
11 |
15 |
| Total Shares Sold |
28,125 |
57,644 |
147,085 |
279,745 |
| Total Sell Value |
$281,621 |
$452,188 |
$1,266,262 |
$3,933,863 |
| Total People Sold |
6 |
6 |
8 |
8 |
| Total Sell Transactions |
12 |
15 |
24 |
56 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tahir Misbah |
Chief Financial Officer |
• – – |
2022-05-13 |
4 |
A |
$12.38 |
$4,841 |
D/D |
391 |
34,648 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
40,428 |
|
- |
|
| Gauthier George |
Chief Commercial Officer |
• – – |
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
26,576 |
|
- |
|
| Decker Lisa Lynn |
Chief Business Officer |
• – – |
2022-05-13 |
4 |
A |
$12.38 |
$5,113 |
D/D |
413 |
22,897 |
|
- |
|
| Topsoe Christina Teng |
Director |
– • • |
2022-05-12 |
4 |
B |
$14.08 |
$32,248 |
I/I |
2,290 |
2,290 |
2.25 |
- |
|
| Topsoe Jakob Haldor |
Director |
– • • |
2022-05-12 |
4 |
B |
$14.17 |
$116,991 |
D/D |
8,254 |
64,131 |
3.92 |
- |
|
181 Records found
|
|
Page 8 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
